带状疱疹治疗市场规模、份额和成长分析（按诊断、治疗/预防、给药途径、最终用户和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，全球带状疱疹治疗市场规模将达到 24.2 亿美元，到 2025 年将达到 26.6 亿美元，到 2033 年将达到 57.1 亿美元，预测期（2026-2033 年）的复合年增长率为 10%。

全球带状疱疹治疗市场正经历强劲成长，主要驱动因素是带状疱疹发病率的上升，尤其是在老年人群中。人们对预防措施和带状疱疹后遗症神经痛管理的认识不断提高，推动了对疫苗和抗病毒治疗的需求。人工智慧等创新技术在研发领域的应用，正在简化药物发现流程，并改善病患的治疗效果。临床试验和疫苗研发的重点在于增强长期免疫力并降低復发率。此外，新兴市场正利用其医疗保健服务的改善和公共疫苗接种政策的优势。儘管目前在研疗法有限，且由于老龄化相关的顾虑和缺乏全民疫苗接种计划，疫苗接受度存在差异，但人口老龄化和重组带状疱疹疫苗的有效性，仍展现出良好的市场前景。

推动全球带状疱疹治疗市场发展的因素

全球带状疱疹治疗市场的发展主要得益于人工智慧 (AI) 对药物研发过程的变革性影响。先进的演算法能够分析大量资料集，包括基因组、蛋白质组和化合物库，从而帮助识别有前景的抗病毒候选药物。这项技术创新可以显着降低临床前和临床开发阶段的成本和时间。因此，许多製药公司和生技Start-Ups公司正在采用人工智慧平台来加强其研究活动，加速开髮用于治疗带状疱疹及其併发症（例如带状疱疹后遗症神经痛(PHN)）的新一代疫苗和治疗方法。

限制全球带状疱疹治疗市场的因素

人工智慧在带状疱疹治疗市场的应用面临着许多挑战，其中最主要的障碍在于严格的法规结构和资料隐私问题，尤其是在演算法开发中如何使用患者资讯。一些地区医疗资料保护法律尤其严格，这往往会阻碍人工智慧在临床实践中的应用，进而可能减缓创新技术的整体普及速度。这些监管方面的挑战阻碍了人工智慧解决方案在该领域的快速发展，最终限制了市场扩张和最先进治疗方法的潜在益处。

全球带状疱疹治疗市场趋势

全球带状疱疹治疗市场正呈现出一个显着的趋势，即整合个人化人工智慧模型以预防带状疱疹后遗症神经痛（PHN）。这些进展利用患者特异性数据，例如免疫反应、遗传易感性和疼痛阈值，来制定量身定制的治疗通讯协定，从而提高疗效。製药公司正致力于透过人工智慧分析真实世界的临床数据来优化药物剂量和改善治疗途径，这不仅将改善患者预后，还将推动市场成长。这种创新方法有望彻底改变带状疱疹及其併发症的治疗方式，并代表治疗领域正在发生的变革。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 一手和二手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球带状疱疹治疗市场规模（按诊断和复合年增长率划分）（2026-2033 年）

• 检查室检测
• 萤光显微镜
• 即时聚合酵素链锁反应（PCR）
• 血清学检测
• 其他的

全球带状疱疹治疗市场规模：治疗与预防及复合年增长率（2026-2033）

• 抗病毒药物
• 麻醉性止痛药
• 抗发炎药
• 抗组织胺药
• 抗惊厥药
• 辣椒素
• 麻醉膏、凝胶或贴片
• 疫苗
• 其他的

全球带状疱疹治疗市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 外用药物
• 其他的

全球带状疱疹治疗市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院诊所
• 诊断中心
• 研究和学术机构
• 居家医疗环境
• 其他的

全球带状疱疹治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • GCC
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

  主要企业简介

  • 葛兰素史克（GSK）（英国）
  • 默克公司（美国）
  • 辉瑞公司（美国）
  • 赛诺菲（法国）
  • 诺华公司（瑞士）
  • 安斯泰来製药株式会社（日本）
  • ModernaTX公司（美国）
  • Dynavax Technologies Corporation（美国）
  • Curevo公司（美国）
  • 江苏瑞克生物科技有限公司（中国）
  • 绿竹生物科技有限公司 (中国)
  • 韩国绿十字公司
  • BioNTech（德国）
  • 百时美施贵宝（美国）
  • 武田药品工业株式会社（日本）
  • SK生物科学（韩国）
  • Vaxine Pty Ltd（澳洲）
  • EpiVax（美国）
  • Virios Therapeutics（美国）
  • WEX製药公司（加拿大）

结论与建议

Global Herpes Zoster Therapeutics Market size was valued at USD 2.42 Billion in 2024 and is poised to grow from USD 2.66 Billion in 2025 to USD 5.71 Billion by 2033, growing at a CAGR of 10% during the forecast period (2026-2033).

The global herpes zoster therapeutics market is witnessing robust growth, largely fueled by the increasing incidence of shingles, particularly in older adults. Heightened awareness regarding preventive measures and management of post-herpetic neuralgia is driving the demand for vaccines and antiviral treatments. Innovations like AI in research are streamlining drug discovery and enhancing patient outcomes. The rise in clinical trials and vaccine development is focusing on improving long-term immunity and reducing recurrence rates. Additionally, emerging markets are capitalizing on improved healthcare access and public vaccination initiatives. Despite the limited number of therapeutic agents in development and inconsistent vaccine acceptance due to factors like age-related fears and lack of universal vaccination programs, the aging population and the effectiveness of recombinant zoster vaccines indicate a promising market outlook.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Herpes Zoster Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Herpes Zoster Therapeutics Market Segments Analysis

Global Herpes Zoster Therapeutics Market is segmented by Diagnosis, Treatment and Prevention, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing and Others. Based on Treatment and Prevention, the market is segmented into Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines and Others. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is being driven by the transformative impact of Artificial Intelligence on drug discovery processes. Advanced algorithms are capable of analyzing vast datasets, encompassing genetic, proteomic, and chemical compound libraries, which facilitates the identification of promising antiviral candidates. This technological innovation significantly minimizes both costs and time linked with preclinical and clinical development phases. As a result, numerous pharmaceutical companies and biotech startups are employing AI-powered platforms to enhance their research efforts, thereby accelerating the creation of next-generation vaccines and therapies aimed at treating shingles and its associated complications, such as post-herpetic neuralgia (PHN).

Restraints in the Global Herpes Zoster Therapeutics Market

The advancement of AI in the herpes zoster therapeutics market faces significant obstacles due to stringent regulatory frameworks and concerns surrounding data privacy, particularly regarding the use of patient information for algorithm development. In regions where health data protection laws are particularly rigorous, the integration of AI in clinical settings is often impeded, which can slow down the overall deployment of innovative technologies. These regulatory challenges may create barriers to the rapid progression of AI-driven solutions in this field, ultimately restricting market expansion and the potential benefits of cutting-edge therapeutic approaches.

Market Trends of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is increasingly witnessing a trend towards the integration of personalized AI models aimed at preventing post-herpetic neuralgia (PHN). These advancements leverage patient-specific data, including immune responses, genetic predispositions, and pain thresholds, to craft tailored treatment protocols that enhance therapeutic efficacy. By utilizing AI to analyze real-world data, pharmaceutical companies are focusing on optimizing medication dosages and treatment pathways, which not only improve patient outcomes but also drive market growth. This innovative approach promises to revolutionize the management of herpes zoster and its complications, reflecting an evolving landscape in the therapeutic domain.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Herpes Zoster Therapeutics Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Laboratory Testing
• Immunofluorescent Microscopy
• Real-Time Polymerase Chain Reaction (PCR)
• Serological Testing
• Others

Global Herpes Zoster Therapeutics Market Size by Treatment and Prevention & CAGR (2026-2033)

• Market Overview
• Antiviral Medications
• Narcotic Medications
• Anti-Inflammatory Medications
• Antihistamines
• Anticonvulsants
• Capsaicin
• Numbing Creams, Gels, or Patches
• Vaccines
• Others

Global Herpes Zoster Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Others

Global Herpes Zoster Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Research & Academic Institutes
• Home Care Settings
• Others

Global Herpes Zoster Therapeutics Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ModernaTX, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luzhu Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EpiVax (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WEX Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations